保稅科技(600794.SH):勝幫凱米合計減持3333.13萬股股份 減持計劃實施完畢
格隆匯5月23日丨保稅科技(600794.SH)公佈,2025年3月3日至2025年5月23日減持計劃實施期間,勝幫凱米通過大宗交易方式減持公司股份2133萬股,佔公司當前總股本的1.7773%;通過集中競價交易方式減持公司股份1200.13萬股,即公司當前總股本的0.99998%;合計減持3333.13萬股,佔公司當前總股本的2.7773%。
本次減持計劃實施完畢後,勝幫凱米持有公司無限售條件流通股6000.76萬股,佔公司總股本的5.0000%。本次減持計劃實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.